Medtech spin-out NSL attracts an investment of $156,000.
NSL, a medical device spin-out of the Engineering Centre of New Technologies and Technospark, has secured a $156,000 investment. Moscow Seed Fund is investing $86,000, with the remaining $70,000 invested by Technospark itself.
NSL has developed a medical laser drill, able to puncture the tip of a finger for blood analysis. The drill is contactless, meaning it significantly minimises the risk of infection as well as reducing the risk of nausea and faintness when drawing the blood. Dubbed ErbiLite, the technology is currently undergoing a study with a view to be fully licensed by the Russian Department of Health.
NSL is expecting its device to save the health care service some $13m per year by doing away with the import of traditional needles and blood lancets. NSL will use the money to scale the production of ErbiLite up to a commercial scale.
Technospark is a nanotech centre officially opened in December 2013, and has several national and international partners such as Leuven, Belgium-based Imec, Moscow-based Physics Instrumentation Centre of the Institute of General Physics and the Russian Academy of Sciences. It is the Moscow Seed Fund’s 30th investment, and its first in a medical devices company.